Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-31falseThe principal activity of the company in the year under review was that of trading and investment inbloodstockfalse0true2023-01-01false0 12634726 2023-01-01 2023-12-31 12634726 2022-01-01 2022-12-31 12634726 2023-12-31 12634726 2022-12-31 12634726 c:Director2 2023-01-01 2023-12-31 12634726 d:CurrentFinancialInstruments 2023-12-31 12634726 d:CurrentFinancialInstruments 2022-12-31 12634726 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 12634726 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 12634726 d:ShareCapital 2023-12-31 12634726 d:ShareCapital 2022-12-31 12634726 d:RetainedEarningsAccumulatedLosses 2023-12-31 12634726 d:RetainedEarningsAccumulatedLosses 2022-12-31 12634726 c:FRS102 2023-01-01 2023-12-31 12634726 c:Audited 2023-01-01 2023-12-31 12634726 c:FullAccounts 2023-01-01 2023-12-31 12634726 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 12634726 c:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 12634726 e:PoundSterling 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure

Registered number: 12634726









K & W BLOODSTOCK LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2023

 
K & W BLOODSTOCK LIMITED
REGISTERED NUMBER: 12634726

BALANCE SHEET
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

  

Current assets
  

Stocks
 4 
374,900
383,270

Debtors: amounts falling due within one year
 5 
10,874
4,165

Cash at bank and in hand
  
909,809
635,698

  
1,295,583
1,023,133

Creditors: amounts falling due within one year
 7 
(335,018)
(335,018)

Net current assets
  
 
 
960,565
 
 
688,115

Total assets less current liabilities
  
960,565
688,115

  

Net assets
  
960,565
688,115


Capital and reserves
  

Called up share capital 
  
2
2

Profit and loss account
  
960,563
688,113

  
960,565
688,115


Page 1

 
K & W BLOODSTOCK LIMITED
REGISTERED NUMBER: 12634726
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 28 November 2024.




Huw Mostyn Leach
Director

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

K & W Bloodstock Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address as found on the Company Information page is Creswell House, Fieldway, Heath, CF14 4UH. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The directors have reviewed the balance sheet and the company's likely future cashflows. At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources in place to continue in operational existence for the foreseeable future. 

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Page 3

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.4

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees




The Company has no employees other than the directors, who did not receive any remuneration (2022 - £NIL).

Page 4

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


Stocks

2023
2022
£
£

Stocks
374,900
383,270

374,900
383,270


Page 5

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

5.


Debtors

2023
2022
£
£


Other debtors
10,874
4,165

10,874
4,165



6.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
909,809
635,698

909,809
635,698



7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Amounts owed to group undertakings
335,018
335,018

335,018
335,018



8.


Controlling party

The directors do not consider there to be an ultimate controlling party. 

The company is a wholly owned subsidiary of Knox & Wells Holdings Limited, a company registered in England and Wales. The smallest and largest group in which the company has been consolidated is Knox & Wells Holdings Limited. Copies of the consolidated financial statements of Knox & Wells Holdings Limited can be obtained from the registered office at Creswell House, Fieldway, Heath, Cardiff, CF14 4UH. 


9.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2023 was unqualified.

The audit report was signed on 2 December 2024 by Brian Garland BA ACA (Senior Statutory Auditor) on behalf of MHA.

MHA is the trading name of MacIntyre Hudson LLP, a limited liability partnership in England and Wales (registered number OC312313). 

Page 6